Track topics on Twitter Track topics that are important to you
BOSTON — A real-world look at the treat-and-extend regimen of anti-VEGF agents for treating neovascular age-related macular degeneration showed improved vision in patients with fewer injections per year, according to a poster presented at the American Society of Retina Specialists meeting. Arsh ad M. Khanani, MD, and colleagues presented a retrospective evaluation of the 4-year results of the RENO study, which evaluated the real-world treatment outcomes of intravitreal Lucentis (ranibizumab, Genentech), Eylea (aflibercept, Regeneron) or Avastin (bevacizumab, Genentech) given as-needed for treating wet AMD.
Original Article: Fewer anti-VEGF injections needed over timeNEXT ARTICLE
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...